longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Huaan Hang Seng Biotech ETF

159102

0.8130.85% ( -0.007 )
Delay Trading: Sep 15, 09:44:54
Start trading
OverviewOverviewNewsNewsPostsPostsWikiWikiRatingsRatingsCompositionCompositionDividendsDividends
LongbridgeAI
  • Weekly Recap | AKESO -5.94%, most brokers rate it buy

    Weekly Review·2 days ago, 07:37 AM
    09926-0.78%
  • Weekly Recap | SKB BIO -5.14%, most brokers rate it buy

    Weekly Review·2 days ago, 07:22 AM
    06990-1.54%
  • Weekly Recap | BEONE MEDICINES -4.18%, consensus target above spot

    Weekly Review·2 days ago, 07:17 AM
    06160-0.28%
  • Weekly Recap | WUXI APPTEC -1.51%, H1 net profit up 33.7%

    Weekly Review·2 days ago, 05:41 AM
    02359-0.86%
  • Weekly Recap | WUXI BIO -3.05%, consensus target above spot

    Weekly Review·2 days ago, 05:33 AM
    02269-0.77%
  • Weekly Recap | INNOVENT BIO -7.65%, most brokers rate it buy

    Weekly Review·2 days ago, 05:24 AM
    01801-0.26%
  • Weekly Recap | 3SBIO -3.74%

    Weekly Review·2 days ago, 05:17 AM
    01530-0.99%
  • Weekly Recap | AKESO +12.57%, ivonescimab hits survival endpoint

    Weekly Review·Sep 5 at 05:56 AM
    09926-0.78%
  • Weekly Recap | BEONE MEDICINES +2.51%, in US pricing deal

    Weekly Review·Sep 5 at 05:36 AM
    06160-0.28%
  • Weekly Recap | WUXI BIO +0.7%, most brokers rate it buy

    Weekly Review·Sep 5 at 05:12 AM
    02269-0.77%
  • Weekly Recap | WUXI APPTEC +0.95%, consensus target above spot

    Weekly Review·Sep 5 at 05:06 AM
    02359-0.86%
  • Weekly Recap | INNOVENT BIO -1.35%, most brokers rate it buy

    Weekly Review·Sep 5 at 04:56 AM
    01801-0.26%
  • Weekly Recap | 3SBIO +0.74%, consensus target above spot

    Weekly Review·Sep 5 at 04:46 AM
    01530-0.99%
  • Weekly Recap | AKESO +7.92%, ivonescimab Phase III hits endpoint

    Weekly Review·Aug 29 at 05:06 AM
    09926-0.78%
  • Weekly Recap | BEONE MEDICINES +1.36%, FDA nod and 385% interim profit jump

    Weekly Review·Aug 29 at 04:52 AM
    06160-0.28%